Cargando…
Aptamers Against COVID-19: An Untested Opportunity
Given the lack of success in the development of effective drugs to treat COVID-19, which show “game-changing” potential, it is necessary to explore drugs with different modes of action. Single mode-of-action drugs have not been succeeded in curing COVID-19, which is a highly complex disease. This is...
Autores principales: | Haberland, Annekathrin, Müller, Johannes |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896377/ https://www.ncbi.nlm.nih.gov/pubmed/35023454 http://dx.doi.org/10.2174/1389557522666220112094951 |
Ejemplares similares
-
Lack of efficacy of mono‐mode of action therapeutics in COVID‐19 therapy ‐ How the lack of predictive power of preclinical cell and animal studies leads developments astray
por: Haberland, Annekathrin, et al.
Publicado: (2021) -
Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
por: Haberland, Annekathrin, et al.
Publicado: (2021) -
Elective Surgery and COVID-19: A Framework for the Untested Patient
por: Lu, Amy C., et al.
Publicado: (2020) -
Importance of untested infectious individuals for interventions to suppress COVID-19
por: Pérez-Reche, Francisco J., et al.
Publicado: (2021) -
Synthesis and Molecular Docking of New N-Acyl Hydrazones-Benzimidazole as hCA I and II Inhibitors
por: Küçükoğlu, Kaan, et al.
Publicado: (2023)